Miller RE - Search Results

1

Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?

Gourley C, Miller RE, Hollis RL, Ledermann JA. Gourley C, et al. Among authors: miller re. Curr Opin Oncol. 2020 Sep;32(5):442-450. doi: 10.1097/CCO.0000000000000660. Curr Opin Oncol. 2020. PMID: 32796232 Review.

2

How to follow-up patients with epithelial ovarian cancer.

Miller RE, Rustin GJ. Miller RE, et al. Curr Opin Oncol. 2010 Sep;22(5):498-502. doi: 10.1097/CCO.0b013e32833ae8b6. Curr Opin Oncol. 2010. PMID: 20498597 Review.

3

Gynecologic Cancers: Emerging Novel Strategies for Targeting DNA Repair Deficiency.

Kristeleit RS, Miller RE, Kohn EC. Kristeleit RS, et al. Among authors: miller re. Am Soc Clin Oncol Educ Book. 2016;35:e259-68. doi: 10.1200/EDBK_159086. Am Soc Clin Oncol Educ Book. 2016. PMID: 27249731 Free article. Review.

4

The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib.

Miller RE, Ledermann JA. Miller RE, et al. Clin Adv Hematol Oncol. 2016 Aug;14(8):619-27. Clin Adv Hematol Oncol. 2016. PMID: 27487106 Review.

5

The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations.

Miller RE, Ledermann JA. Miller RE, et al. Clin Adv Hematol Oncol. 2016 Sep;14(9):704-11. Clin Adv Hematol Oncol. 2016. PMID: 27673289 Review.

6

The European Society for Medical Oncology (ESMO) Congress 2016: Highlights and summary of selected abstracts in gynecologic cancers.

Miller RE, Ledermann JA. Miller RE, et al. Gynecol Oncol. 2017 Jan;144(1):8-10. doi: 10.1016/j.ygyno.2016.11.040. Epub 2016 Nov 27. Gynecol Oncol. 2017. PMID: 27903404 No abstract available.

7

Olaparib maintenance for first-line treatment of ovarian cancer: will SOLO1 reset the standard of care?

Miller RE, Crusz SM, Ledermann JA. Miller RE, et al. Future Oncol. 2019 Jun;15(16):1845-1853. doi: 10.2217/fon-2019-0057. Epub 2019 Apr 30. Future Oncol. 2019. PMID: 31037967

8

Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors.

Lord R, Rauniyar J, Morris T, Condon O, Jones R, Miller R, Hall M, Lofts F, Glasspool RM, Hudson E. Lord R, et al. Int J Gynecol Cancer. 2020 Jul;30(7):1026-1033. doi: 10.1136/ijgc-2019-000973. Epub 2020 Apr 21. Int J Gynecol Cancer. 2020. PMID: 32321768

9

ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.

Miller RE, Leary A, Scott CL, Serra V, Lord CJ, Bowtell D, Chang DK, Garsed DW, Jonkers J, Ledermann JA, Nik-Zainal S, Ray-Coquard I, Shah SP, Matias-Guiu X, Swisher EM, Yates LR. Miller RE, et al. Ann Oncol. 2020 Dec;31(12):1606-1622. doi: 10.1016/j.annonc.2020.08.2102. Epub 2020 Sep 28. Ann Oncol. 2020. PMID: 33004253 Free article.

10

PARP inhibitors and immunotherapy in ovarian and endometrial cancers.

Miller RE, Lewis AJ, Powell ME. Miller RE, et al. Br J Radiol. 2021 Dec;94(1128):20210002. doi: 10.1259/bjr.20210002. Epub 2021 Jun 9. Br J Radiol. 2021. PMID: 33882241 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

718 results

Search Page